Zivo Bioscience EBIT

The latest EBIT for ZIVO is $-5.5M as of June 2026. That compares with $-9.7M in the prior-year period — up 43.4% year over year. That is below the Consumer Discretionary sector average of $17T. Investors often review this figure alongside Zivo Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZIVO's EBIT moved from $-9.7M to $-5.5M — a 43.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zivo Bioscience's operating scale or balance-sheet position.

Against Consumer Discretionary companies, ZIVO currently prints $-5.5M for EBIT, while the sector average sits near $17T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Zivo Bioscience's growth, margins, and balance sheet.

A EBIT figure of $-5.5M for ZIVO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Consumer Discretionary average is about $17T. Explore the charts below for those layers of context.

After noting ZIVO's EBIT ($-5.5M), review year-over-year change from $-9.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.